Oct 30 (Reuters) - Sarepta Therapeutics' gene therapy to treat Duchenne muscular dystrophy failed to reach statistical significance in a late-stage trial, the company reported after the bell on Monday. (Reporting by Pratik Jain; Editing by Krishna Chandra Eluri)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Nancy Pelosi's husband Paul Pelosi uses an investing strategy that lowers upfront costs.
A month after a higher state minimum wage for fast-food workers went into effect, consumers picking up burgers and burritos at chains in the Golden State grapple with prices rising at a faster clip than in other states.
In addition to economic and earnings news, inflation and geopolitical worries will have roles to play.
If you have inherited retirement assets, have a Roth 401(k) or want to give retirement money to charity, you may be impacted by tweaks to this year’s rules for RMDs.
Here's what could happen next to Alphabet shares.
The $50 million purchase could turn into Nvidia's biggest investment.
Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.
The tobacco giant will soon be allowed to sell a proven product in a proven market.
The number probably isn't anywhere near what you think it is.